AYTU BIOPHARMA, INC Accounts Receivable, before Allowance for Credit Loss
AYTU BIOPHARMA, INC (AYTU) had Accounts Receivable, before Allowance for Credit Loss of $23.64 million as of 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AccountsReceivableGross · last filed 2026-09-22
- 2026-06-30: Accounts Receivable, before Allowance for Credit Loss $23.64M.
- 2025-06-30: Accounts Receivable, before Allowance for Credit Loss $32.34M.
- 2024-06-30: Accounts Receivable, before Allowance for Credit Loss $25.35M; Accounts Receivable, before Allowance for Credit Loss as first filed $25.44M.
- 2023-06-30: Accounts Receivable, before Allowance for Credit Loss $31.72M; Accounts Receivable, before Allowance for Credit Loss as first filed $31.93M.
| Period end | Accounts Receivable, before Allowance for Credit Loss | Accounts Receivable, before Allowance for Credit Loss as first filed |
|---|---|---|
| 2026-06-30 | $23.64M 10-K · filed 2026-09-22 | |
| 2025-06-30 | $32.34M 10-K · filed 2026-09-22 | |
| 2024-06-30 | $25.35M 10-K · filed 2026-09-22 | $25.44M 10-K · filed 2024-09-26 |
| 2023-06-30 | $31.72M 10-K · filed 2025-09-23 | $31.93M 10-K · filed 2023-10-12 |
| 2022-06-30 | $24.22M 10-K · filed 2024-09-26 | |
| 2021-06-30 | $30.32M 10-K · filed 2023-10-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |